---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-035716"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T03:50:18.129946+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lixte Biotechnology terminates exclusive MDS license with Moffitt; no termination fee

## Summary
- Received counter-signed termination letter on Oct 4, 2023, effective Sept 30, 2023.
- No termination fee or further payments owed by Lixte under the license agreement.
- Company had previously disclosed discontinuation of MDS development in June 30, 2023 10-Q.
- License originally granted in August 2018 covering patents for myelodysplastic syndrome.

## SEC filing metadata
- accession: 0001493152-23-035716
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315223035716/0001493152-23-035716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315223035716/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-035716
- JSON: https://secwatch.observer/filing/0001493152-23-035716.json
- Plain text: https://secwatch.observer/filing/0001493152-23-035716.txt

## Key facts
- Material Agreements
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. terminated Exclusive License Agreement with H. Lee Moffitt Cancer Center and Research Institute, Inc. valued at No termination fee payable; no further payments owed by Company. (effective 2023-09-30).
  - Action: termination
  - Agreement: license
  - Counterparty: H. Lee Moffitt Cancer Center and Research Institute, Inc.
  - Value: No termination fee payable; no further payments owed by Company.
  - Effective: 2023-09-30
  source text: On October 4, 2023, Lixte Biotechnology Holdings, Inc. (the “Company”) received a counter-signed termination letter dated September 29, 2023 (the “Termination Letter”) with respect to the Exclusive License Agreement dated August 20, 2018 (the “License Agreement”) between the Company and H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), effective September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315223035716/0001493152-23-035716-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.